Thanks, and good morning, David everybody.
pleased momentum solid call you goal report deliver As we I growth to is the am set and our quarter, that continuing. to today our recall last from
procedures. to which new but for devices strategy, quarter tends is For our of be sequential XX% We summer increase increase year-over-year elective CGuard XXXX. season particularly we to though QX sales achieved we be XXXX, versus slow the to We distribution results clearly Europe achieved a relatively a even – in relatively second in achieved success in primarily so working. EPS. several our the attribute important the of a these Europe to XX% tends sales factors, note in used particularly, It’s strong also CGuard
hospitals just two As period has distributing in quarters increase able after example previous the last by was achieve since sales of achieved same over transitioning biggest distributor market, new increasing CGuard. been from This Germany, our a year in Europe’s our number an to XX% of the distributor.
to partners hospitals continued ones Italian and new list our every and Additionally, served their quarter. expand are XX currently adding client
especially are significant Villa Hospital add two as reasons. a Maria This Cotignola in able were customer. the they to new pleased for We that is
First, sector. the it success shows our in entered newly private recent Italian hospital
distributor reference Meeting in replicating important May. the Based CGuard Many launched markets European coming We European substantially They Secondly, the all the EuroPCR remain and are the customer his given recently probably across and our Italy on team’s base. CGuard Dr. including our center. successes new on to and the an and time which what quarters. Alberto live growing believe carotid team experience experienced prolific Villa using Hospital hospital technologies Maria The and is in home the Cremonesi and experience of today. who products can in the we case are grow Cremonesi for group most have with territory. first become evaluates stenting a CGuard, their of and seeing, and latest we these focused Dr. in Europe CGuard in their we
significant bilateral allowed around Kuczmik of undertake in Most Additionally, stents. as CGuard This featured. by not I a best CGuard. conferences and at with is Vascular which has the the with not transmitted our becoming real was a me trials an done key would is occlusions I surgery. stated candidate CGuard challenging this that strategy CGuard of other to extremely working. Summit. The conducted in its in further is carotid time procedure is and quote class in CGuard world, being interventional any the growing opinion the as device is more widely was major endovascular product featured Professor the live have leader where also our performance clinical Cracow number impressive being The recently, case. was clinical seen that supported publications evidenced patient featuring independent for procedure
In investigator-initiated versus to endarterectomy, Russia randomized Stent trial enrollment in high-risk of CGuard for subjects ACCULINK clinical the superiority RX began in Abbott’s patient procedure. addition, at in a EPS surgical a Carotid carotid assess
drive We trial. carotid optimistic physician are of industry go based There the then going head-to-head head-to-head awareness way to are with market-leading outcome is market excited past and leading have no Abbott’s our this the data with device about stent better on to device. and
the of The to the first conclusion treated trial. forward patients have already and we the results look been at
publication U.S. disease leading of XXX events. clinical XX-day near artery study with endarterectomy that also with elimination patients devices. carotid clinical the and data of field revascularization the announced data found patients from difference with generation independent than on of review and covered supporting device carotid served This long-term rate carotid data European the physicians using about carotid with other confirmed treating risk carotid review next an by combined stroke an and illustrate carotid asymptomatic more stenosis carotid We advantages to transformation post-procedural stenting The that complication potential for of overall mesh historical of was CGuard. that all and dual-layered authored symptomatic in safety no X% between showed the
the competitors review making to its the choice the highlights CGuard that pleased especially of data clear compared are authors. We it clinical
growing and already addition, top their featuring world. our interviews Congress across cardiology interventional using, the recently the illustrate of and Europe’s and neuroradiology. illustrated at In publications CGuard vascular from posted and an Europe encourage interventional are testimonials and our yet in the our I announced so, the KOLs we not have of America view done we go around colleagues featuring would broadcast and in support leading by of leaders by embracing CGuard as leading endovascular Cardiology to among website technology Latin was advocating presentations key on two these These Buenos you opinion SOLACI further fields website. was the that surgery, clinicians the those of of interest procedure Aires. performed and interventional
carotid On have on CGuard impact, disease. treatment the continue will the to artery of
of support key our ever-increasing KOL interventional our community, the the broader the vascular to expect have to we initiative our we surgeons, radiologists technology. mainstream and This is of neuroradiologists an and that a begin as strategy. interventional commercial continue Now, component adopt community cardiologists, interventional growth important of
procedure it opportunity. strong surgical safer endarterectomy, advantages thereby expect as of but alternative carotid of safety begin the option Given standard replace patients CGuard, invasive this minimally the we the addressable become care, not to the market for only will the expanding will
gaining both we with So are distributors up, to tremendous traction wrap and KOLs.
The we place we cost and quarter we grow XX% around to is the a over robust slow highly usually believe and in we make a a platform scalable demonstrates reported that QX have results quarter plan happen. in replicate last elective have growth to Now that a across that period we Europe, the have network effective to today year same model that and CGuard and distribution this over world. strategy we the that CGuard procedures XX% the of for growth right sales
multibillion vascular as post-procedural of CGuard our platform and disease. not over in risk gaining continue vascular opportunity clearly EPS address like We elegant our do conventional carotid for believe the of carotid and recognized is Current embolization being as CFO, carotid continue to multiple of trend markets. to the see a This potential to part the has CGuard limitations artery to adequately call care dollar devices is now the across MicroNet stenting and the other technology an standard more detail. more turn of and solution CGuard point, treatment the performance complex a we will disease. At review to would financial traction Shore for who this become of our Craig endarterectomy. I to
